Studies sexual function in men with prostate cancer receiving radiation and hormone therapy
Looks at sexual function in men with prostate cancer receiving radiation and hormone therapy.
Plain-language title generated from the registry record
Registry title: PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer
Key facts
- Where
- Winnipeg, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with a specific type of prostate cancer (unfavorable intermediate risk) who plan to have radiation therapy and hormone therapy. It studies the effect on sexual function.
- Age
- 18 to 80 years
- Sex
- Men only
- Disease stage
- Prostate cancer confirmed by biopsy, unfavorable intermediate risk: Gleason score 7 (4+3), PSA 10-20 ng/mL, or clinical stage T2b-T2c. No metastatic disease.
- Earlier treatment
- Planned treatment with SBRT (36.25-37.5 Gy in 5 fractions) and ADT for 6 months. Cannot have had pelvic radiotherapy, prostate surgery, ADT or chemotherapy before.
- Biomarker or test result
- Sexual function score IIEF-5 of 12 or higher, or an erection status score of 1-3 before the study. Testosterone must not be below the normal range.
Main reasons for not taking part
- Severe sexual dysfunction before the study (IIEF-5 score below 12, or no erection)
- Low testosterone (hypogonadism) at the start
- Metastatic disease, second cancer or earlier cancers
- Medicines that change ejaculation, such as 5-alpha reductase inhibitors
- Penile diseases, or conditions that make SBRT or ADT unsafe
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07460726, who can take part
Where in Canada
- Manitoba Prostate CentreWinnipeg, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CancerCare Manitoba
- Trial code
- NCT07460726
- Record updated
- 10 March 2026
- Original description
This study looks at how combined radiation and hormone therapy affects sexual function in men with a specific type of prostate cancer, before and after treatment.Read full original descriptionShow less
A Single Arm Prospective Study to Investigate the Impact of Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) on Sexual Dysfunction in Unfavorable Intermediate Risk Prostate Cancer
This study looks at how combined radiation and hormone therapy affects sexual function in men with a specific type of prostate cancer, before and after treatment.
Inclusion: Men aged 18-80 years with biopsy-proven UIR-PCa (National Comprehensive Cancer Network [NCCN] criteria: Gleason score 7 (4+3), PSA 10-20 ng/mL, or clinical stage T2b-T2c); Planned treatment with SBRT (36.25-37.5 Gy in 5 fractions) and ADT (6 months); Baseline sexual function assessment available (International Index of Erectile Function [IIEF-5, also known as SHIM] score ≥ 12 or pre-selection erection status score of 1-3: erection insufficient for intercourse, sufficient but not optimal, or normal); Eastern Cooperative Oncology Group (ECOG) performance status 0-1; Written informed consent to participate.
Exclusion: Prior pelvic radiotherapy, prostate surgery, ADT, or chemotherapy; Use of medications altering ejaculation (e.g., 5-alpha reductase inhibitors); Metastatic disease, second malignancy, or previous malignancies; Benign or malignant penile diseases; Psychiatric conditions affecting questionnaire completion or QoL assessment; Severe comorbidities affecting QoL assessments (e.g., advanced cardiovascular disease); Pre-existing severe sexual dysfunction (IIEF-5 score < 12 or pre-selection erection status score of 0: no erection); Hypogonadism at presentation (baseline testosterone below normal range); Contraindications to SBRT or ADT.